Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.49 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14991056 | 0.77 | CYP19A1 (0.51) | CYP19A1UGT1A4PDE4DHDAC1HDAC6 | |
| SCHEMBL7081887 | 0.76 | CYP19A1 (0.64) | CYP19A1UGT1A4PDE4DHDAC1HDAC6 | |
| SCHEMBL3115446 | 0.75 | CYP19A1 (0.65) | CYP19A1UGT1A4PDE4DHDAC1HDAC6 | |
| SCHEMBL305624 | 0.75 | CYP19A1 (0.65) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL10172609 | 0.75 | CYP19A1 (0.82) | CYP19A1UGT1A4PDE4D | |
| SCHEMBL3318872 | 0.74 | CYP19A1 (0.67) | CYP19A1UGT1A4PDE4DHDAC1HDAC6 | |
| SCHEMBL306232 | 0.74 | CYP19A1 (0.67) | CYP19A1UGT1A4PDE4DHDAC1HDAC6 | |
| SCHEMBL12908863 | 0.73 | CYP19A1 (0.85) | CYP19A1UGT1A4PDE4D | |
| SCHEMBL28786049 | 0.73 | CYP11B1 (0.50) | CYP19A1UGT1A4PDE4DCYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL11228283 | 0.73 | CYP19A1 (0.65) | CYP19A1UGT1A4PDE4DHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | CYP19A1 605/4885UGT1A4 2132/4885PDE4D 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.